Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

• Status: Completed
• Trial end date: 2003-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Treatments: Interferon beta-1a; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Must have been receiving AVONEX® or Rebif®.

• Must have a confirmed diagnosis of relapsing-remitting MS using the Poser criteria.

• Must have experienced at least 2 relapses within the 3 year period prior to the initiation of treatment.

• Must have an EDSS score of 0.0 to 5.5, inclusive.

Exclusion Criteria:

• History of severe allergic or anaphylactic reaction or hypersensitivity to human albumin, to any interferon, or to other components of the drug formulation.

• History of poorly controlled hypertension and/or other clinically significant major disease.

• History of uncontrolled seizures within the 3 months prior to enrollment.

• History of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment.

• Serious local infection or systemic infection within 8 weeks prior to enrollment.

• Treatment with certain other agents to treat MS symptoms or underlying disease.

• Treatment with any investigational product

• Previous participation in this study.

• Other Protocol-defined inclusion/exclusion criteria may apply.